All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Harris is seeing an uptick in support from Black women voters who support her efforts to protect abortion and expand prenatal ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

As prices for Ozempic have risen in recent months, many people may be seeking cheaper alternatives for managing diabetes or ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

Nearly 250,000 people in England could access a weight loss injection on the NHS. Tirzepatide is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss.

The drug uses the active ingredient tirzepatide and was approved by the FDA in May 2022 for type 2 diabetes; although McCaskill said her blood sugar was elevated, she didn’t have diabetes ...